Atossa Therapeutics (NASDAQ:ATOS) Downgraded to “Sell” Rating by StockNews.com

StockNews.com cut shares of Atossa Therapeutics (NASDAQ:ATOS) from a hold rating to a sell rating in a research note released on Friday morning.

Several other equities analysts have also recently weighed in on ATOS. Ascendiant Capital Markets lifted their price objective on Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a report on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Atossa Therapeutics in a research report on Thursday, October 31st.

Atossa Therapeutics Price Performance

Shares of ATOS remained flat at $1.50 during mid-day trading on Friday. 548,812 shares of the stock traded hands, compared to its average volume of 1,076,483. Atossa Therapeutics has a twelve month low of $0.62 and a twelve month high of $2.31. The stock has a market capitalization of $188.64 million, a PE ratio of -7.14 and a beta of 1.23. The business has a 50 day simple moving average of $1.44 and a 200-day simple moving average of $1.38.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. As a group, analysts anticipate that Atossa Therapeutics will post -0.22 EPS for the current year.

Hedge Funds Weigh In On Atossa Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Intech Investment Management LLC bought a new stake in Atossa Therapeutics during the third quarter worth approximately $29,000. SG Americas Securities LLC grew its holdings in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after acquiring an additional 30,037 shares during the period. XTX Topco Ltd purchased a new position in shares of Atossa Therapeutics during the 2nd quarter valued at approximately $29,000. Renaissance Technologies LLC lifted its holdings in Atossa Therapeutics by 11.9% during the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after purchasing an additional 164,540 shares in the last quarter. Finally, Rhumbline Advisers acquired a new stake in Atossa Therapeutics during the second quarter worth about $161,000. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.